

Lower tear meniscus measurements using a new anterior segment swept-source optical coherence tomography and agreement with fourier-domain optical coherence tomography

Pedro Arriola-Villalobos, MD, PhD
José Ignacio Fernández-Vigo, MD, PhD
David Díaz-Valle, MD, PhD
Jaime Almendral-Gómez, MD
José M. Benítez-del-Castillo, MD, PhD.
Ophthalmology, Hospital Clínico San Carlos, Madrid, Spain.

Cristina Fernández-Pérez, MD, PhD
Investigative Support Unit, Hospital Clínico San Carlos, Madrid, Spain

Purpose

To assess intraobserver repeatability and interobserver and intersession reproducibility of lower tear meniscus height (LTMH) measurements obtained using the new anterior segment swept-source (SS) optical coherence tomography (OCT) DRI OCT Triton (Topcon, Inc., Tokyo, Japan). Agreement with Fourier-domain (FD) OCT (Spectralis) was also examined.

Methods

In an observational cross-sectional study one eye of 29 healthy subjects was randomly imaged with both devices at our centre. Two examiners then randomly took LTMH measurements using the software's callipers. To assess intraobserver repeatability and interobserver and intersession reproducibility within-subject standard deviation (Sw), test-retest repeatability, coefficients of variation (CoV) and intraclass correlation coefficients (ICC) were calculated. Agreement between both devices was also determined in Bland-Altman plots.

Results

Mean LTMH for SS-OCT and FD-OCT were 276.6 ± 87.57 microns and 280.31 ± 79.99 microns, respectively. Using the SS-OCT device, intraobserver CoV, interobserver CoV and intersession CoV were 16.9%, 7.2% and 11.5% respectively. ICCs for these parameters were 88%, 97% and 94%, respectively. Bland-Altman analysis indicated poor agreement between SS-OCT and FD-OCT, and correlation was low (CoV 34.5%, ICC 0.36).

Conclusion

SS-OCT LTMH measurements showed excellent interobserver and intersession repeatability along with good intraobserver reproducibility. Agreement between the devices was poor.

Financial disclosure

The authors have no commercial or proprietary interest in any of the products or companies mentioned in this article.